Novavax Inc NVAX shares are trading higher Tuesday. The company announced that its protein-based Covid-19 vaccine received Emergency Use Listing (EUL).
What Happened: The World Health Organization (WHO) granted Novavax EUL for active immunization to prevent Covid-19 in those 12 years of age and older. The EUL enables the WHO's 194 member states to expedite regulatory approvals to import and administer the vaccine.
"Rural or hard-to-reach areas can benefit from our vaccine's ease of transport and storage profile. As part of a diversified vaccine portfolio, our vaccine can play an important role in helping to protect people around the globe against the latest variants," said John Jacobs, president and CEO of Novavax.
The EUL was based on non-clinical data showing that Novavax's vaccine induced functional immune responses against multiple Covid variants and induced neutralizing antibody responses to several subvariants. Such shows that the vaccine can stimulate both parts of the immune system and may induce a broad response against current variants.
From Last Week: Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls
NVAX Price Action: Novavax shares were up 1.83% at $5.56 at the time of writing, according to Benzinga Pro.
Photo: Marco Verch from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.